Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.

Article Details

Citation
Copy to clipboard

Zacche MM, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A

Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.

Gynecol Endocrinol. 2009 Aug;25(8):508-13. doi: 10.1080/09513590903015544.

PubMed ID
19551544 [ View in PubMed
]
Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common endocrine cause of hirsutism, acne and pattern alopecia, often characterised by ovulation disorders (usually manifested as oligo- or amenorrhea). In addition, 30-40% of women with PCOS have impaired glucose tolerance, and a defect in the insulin signalling pathway seems to be implicated in the pathogenesis of insulin resistance. For this reason, insulin-lowering medications represent novel approach in women with PCOS. The aim of this study was to evaluate the effects of myo-inositol (MYO), an isoform of inositol, belonging to the vitamin B complex, in the treatment of cutaneous disorders like hirsutism and acne. METHODS: Fifty patients with PCOS were enrolled in the study. BMI, LH, FSH, insulin, HOMA index, androstenedione, testosterone, free testosterone, hirsutism and acne were evaluated at the baseline and after receiving MYO therapy for 6 months. RESULTS: After 3 months of MYO administration, plasma LH, testosterone, free testosterone, insulin and HOMA index resulted significantly reduced; no significant changes were observed in plasma FSH and androstenedione levels. Both hirsutism and acne decreased after 6 months of therapy. DISCUSSION: MYO administration is a simple and safe treatment that ameliorates the metabolic profile of patients with PCOS, reducing hirsutism and acne.

DrugBank Data that Cites this Article

Drugs